Anbio Biotechnology (NASDAQ:NNNN) Sees Large Growth in Short Interest

Posted by Jessica Moore on Sep 14th, 2026

Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 58,423 shares, an increase of 122.9% from the August 15th total of 26,210 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 286,803 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Anbio Biotechnology currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on NNNN

Anbio Biotechnology Stock Performance

Shares of NNNN traded down $0.01 during mid-day trading on Monday, reaching $6.33. The stock had a trading volume of 31,269 shares, compared to its average volume of 69,414. The business has a fifty day moving average of $8.99 and a 200 day moving average of $18.73. Anbio Biotechnology has a 12 month low of $6.13 and a 12 month high of $51.33.

About Anbio Biotechnology

(Get Free Report)

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.